JMJake Peter Mann

Jake Peter Mann

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jake Peter Mann has a total of 295 co-authors. Here are the top co-authors by number of shared publications:

  • Amedine Duret

    School of Clinical Medicine,University of Cambridge,Cambridge,United Kingdom

    7 shared publications
  • Jiawen Dong

    School of Clinical Medicine,University of Cambridge,Cambridge,United Kingdom

    7 shared publications
  • Yu Ri Im

    School of Clinical Medicine,University of Cambridge,Cambridge,United Kingdom

    7 shared publications
  • Anita Vreugdenhil

    Center for Overweight Adolescent and Children's Health Care,Department of Pediatrics,Maastricht University Medical Center,Maastricht,the Netherlands

    6 shared publications
  • Dana de Gracia Hahn

    School of Clinical Medicine,University of Cambridge,Cambridge,United Kingdom

    6 shared publications
  • Deirdre A. Kelly

    Liver Unit,Birmingham Womens and Children’s Hospital Trust,Birmingham,UK

    6 shared publications

Latest Publications

  • Open Access

    European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) position paper on screening, diagnosis and investigation of paediatric metabolic dysfunction‐associated steatotic liver disease

    by Jake P. Mann, Sander Lefere, Maarten Buytaert, Anna Alisi, Cigdem Arikan, Jernej Brecelj, Rachel M. Brown, Irene Degrassi, Giulia Fiore, Emer Fitzpatrick, et al.

    Metabolic dysfunction‐associated steatotic liver disease (MASLD) is the most common reason for elevated liver enzymes in children in Europe, affecting more than 5% of all children. Since the last iteration of this position paper, there have been substantial advances in our understanding of the disease. After a detailed literature review and thorough discussion, we established consensus recommendations for the diagnosis and assessment of MASLD in children. Alanine aminotransferase (ALT) ≥ 30 IU/L is a suitable screening test for MASLD in children over 10 years of age with obesity (body mass index z ‐score ≥+2), or in children of any age with additional risk factors. All patients with suspected MASLD should be assessed for alternative or concomitant diagnoses, as well as comorbidities. Patients who are not overweight, under 8 years old, or have any other red flags should be promptly referred for specialist assessment. Liver biopsy remains the gold standard for diagnosis and staging of MASLD, but should be reserved for diagnostic uncertainty, to guide treatment decisions, and risk stratification (e.g., prior to transition to adult care). While there is emerging data for non‐invasive tests (e.g., transient elastography), it is unclear how to routinely implement these investigations in clinical practice. Combined changes of ≥20% in both ALT and gamma‐glutamyl transferase may represent a useful non‐invasive tool for monitoring disease severity over time. Most patients are appropriately investigated and managed by non‐specialists where the focus is on holistic management of obesity and its complications. Future research should focus on how to use non‐invasive tests to risk‐stratify children, in particular, how to identify those with advanced fibrosis.


  • Open Access

    Multi-ancestry genome-wide association meta-analysis of hepatocellular carcinoma identifies eight risk loci including MAP3K9, DHRS1, MTTP, and 8q24.21

    by Ifechukwuamaka Chinaka, Annabelle Schofield, Christopher I. Amos, Lewis R. Roberts, Vincent L. Chen, Younghun Han, Manal Hassan, Shishir Shetty, Jake P. Mann

  • Open Access

    Conserved Ductular Reaction Mechanisms in Biliary Atresia and Primary Sclerosing Cholangitis Derived From Single-Cell and Spatial Transcriptomics

    by Annabelle Schofield, Binita M. Kamath, Sonya A. MacParland, Michael Trauner, Palak Trivedi, Jake Peter Mann


  • Top Cited Papers
    Open Access

    Update in clinical science: MASLD in children and adolescents

    by Sander Lefere, Bart G.P. Koot, Jake P. Mann, Philip Bufler, Ruth De Bruyne, Christian A. Hudert


  • Open Access

    Multi-ancestry genome-wide association meta-analysis of hepatocellular carcinoma identifies eight novel risk genes including MYC , MAP3K9 , DHRS1 , and MTTP

    by Ife Chinaka, Annabelle Schofield, Christopher Amos, Roberts Lewis, Vincent L Chen, Younghun Han, Manal Hassan, Shishir Shetty, Jake P Mann

    Background & Aims: Hepatocellular carcinoma (HCC) is the third top cause of cancer death globally, often arising on a background of cirrhosis. Here, we aimed to establish novel genetic drivers of HCC across ancestries at a population level through a large meta-analysis of all-cause HCC. Approach & Results: We included 15 cohorts comprising 17,329 HCC cases and 2,424,298 controls in this meta-analysis. We found 15 genome-wide significant (P < 5x10 -8 ) germline loci, 6 novel in/near GCKR , MTTP , ADH5 , MYC , MAP3K9 , and GABPB2 . MAP3K9 , TERT , and GABPB2 variants act independently of cirrhosis on both co-localisation analysis and sensitivity analyses. There was significant ancestral heterogeneity in 6 loci including variants in the HLA locus that had divergent effects on HCC risk between East Asian and European ancestries. Fine-mapping identified 11 potentially causal coding variants, including p.Leu446Pro in GCKR and p.Asp418Glu in MEN1. MEN1 , MYC , and TERT are all involved in the beta-catenin pathway transactivation complex. Transcriptome-wide analysis identified enrichment of germline-encoded DHRS1 in HCC. Regulome-wide analysis replicated the germline signal for EPHA2 and found a novel chromatin accessible region containing genes ZNF367 and HABP4 . Finally, we demonstrated that population-level genetic architecture for HCC overlaps with steatotic and viral liver disease, and individuals with genetic risk for lower BMI have higher risk of HCC. Conclusions: Genetic risk for HCC is determined by germline susceptibility to beta-catenin pathway activation and cirrhosis. HCC is driven by both heterogenous and homogenous genetic factors across ancestries, which require further ancestral diversity in liver GWAS to fully dissect.

  • Open Access

    A mouse model of human mitofusin-2-related lipodystrophy exhibits adipose-specific mitochondrial stress and reduced leptin secretion

    by Jake P Mann, Xiaowen Duan, Satish Patel, Luis Carlos Tábara, Fabio Scurria, Anna Alvarez-Guaita, Afreen Haider, Ineke Luijten, Matthew Page, Margherita Protasoni, et al.

    Mitochondrial dysfunction has been reported in obesity and insulin resistance, but primary genetic mitochondrial dysfunction is generally not associated with these, arguing against a straightforward causal relationship. A rare exception, recently identified in humans, is a syndrome of lower body adipose loss, leptin-deficient severe upper body adipose overgrowth, and insulin resistance caused by the p.Arg707Trp mutation in MFN2, encoding mitofusin 2. How the resulting selective form of mitochondrial dysfunction leads to tissue- and adipose depot-specific growth abnormalities and systemic biochemical perturbation is unknown. To address this, Mfn2R707W/R707W knock-in mice were generated and phenotyped on chow and high fat diets. Electron microscopy revealed adipose-specific mitochondrial morphological abnormalities. Oxidative phosphorylation measured in isolated mitochondria was unperturbed, but the cellular integrated stress response was activated in adipose tissue. Fat mass and distribution, body weight, and systemic glucose and lipid metabolism were unchanged, however serum leptin and adiponectin concentrations, and their secretion from adipose explants were reduced. Pharmacological induction of the integrated stress response in wild-type adipocytes also reduced secretion of leptin and adiponectin, suggesting an explanation for the in vivo findings. These data suggest that the p.Arg707Trp MFN2 mutation selectively perturbs mitochondrial morphology and activates the integrated stress response in adipose tissue. In mice, this does not disrupt most adipocyte functions or systemic metabolism, whereas in humans it is associated with pathological adipose remodelling and metabolic disease. In both species, disproportionate effects on leptin secretion may relate to cell autonomous induction of the integrated stress response.


  • Open Access

    Reply

    by Christian A. Hudert, Jake P. Mann


  • Open Access

    A minority of somatically mutated genes in pre‐existing fatty liver disease have prognostic importance in the development of NAFLD

    by Jake P. Mann, Matthew Hoare

    Background: Understanding the genetics of liver disease has the potential to facilitate clinical risk stratification. We recently identified acquired somatic mutations in six genes and one lncRNA in pre‐existing fatty liver disease. We hypothesised that germline variation in these genes might be associated with the risk of developing steatosis and contribute to the prediction of disease severity. Methods: Genome‐wide association study (GWAS) summary statistics were extracted from seven studies (>1.7 million participants) for variants near ACVR2A , ALB , CIDEB , FOXO1 , GPAM , NEAT1 and TNRC6B for: aminotransferases, liver fat, HbA1c, diagnosis of NAFLD, ARLD and cirrhosis. Findings were replicated using GWAS data from multiple independent cohorts. A phenome‐wide association study was performed to examine for related metabolic traits, using both common and rare variants, including gene‐burden testing. Results: There was no evidence of association between rare germline variants or SNPs near five genes ( ACVR2A , ALB , CIDEB , FOXO1 and TNRC6B ) and risk or severity of liver disease. Variants in GPAM (proxies for p.Ile43Val) were associated with liver fat ( p = 3.6 × 10 −13 ), ALT ( p = 2.8 × 10 −39 ) and serum lipid concentrations. Variants in NEAT1 demonstrated borderline significant associations with ALT ( p = 1.9 × 10 −11 ) and HbA1c, but not with liver fat, as well as influencing waist‐to‐hip ratio, adjusted for BMI. Conclusions: Despite the acquisition of somatic mutations at these loci during progressive fatty liver disease, we did not find associations between germline variation and markers of liver disease, except in GPAM. In the future, larger sample sizes may identify associations. Currently, germline polygenic risk scores will not capture data from genes affected by somatic mutations.


  • Open Access

    Variants in mitochondrial amidoxime reducing component 1 and hydroxysteroid 17‐beta dehydrogenase 13 reduce severity of nonalcoholic fatty liver disease in children and suppress fibrotic pathways through distinct mechanisms

    by Christian A. Hudert, Leon A. Adams, Anna Alisi, Quentin M. Anstee, Annalisa Crudele, Laura G. Draijer, EU‐PNAFLD investigators, Samuel Furse, Jan G. Hengstler, Benjamin Jenkins, et al.

    Genome‐wide association studies in adults have identified variants in hydroxysteroid 17‐beta dehydrogenase 13 (HSD17B13) and mitochondrial amidoxime reducing component 1 (MTARC1) as protective against nonalcoholic fatty liver disease (NAFLD). We aimed to test their association with pediatric NAFLD liver histology and investigate their function using metabolomics. A total of 1450 children (729 with NAFLD, 399 with liver histology) were genotyped for rs72613567T>TA in HSD17B13, rs2642438G>A in MTARC1, and rs738409C>G in patatin‐like phospholipase domain‐containing protein 3 (PNPLA3). Genotype–histology associations were tested using ordinal regression. Untargeted hepatic proteomics and plasma lipidomics were performed in a subset of children. We found rs72613567T>TA in HSD17B13 to be associated with lower odds of NAFLD diagnosis (odds ratio, 0.7; 95% confidence interval, 0.6–0.9) and a lower grade of portal inflammation (p < 0.001). rs2642438G>A in MTARC1 was associated with a lower grade of hepatic steatosis (p = 0.02). Proteomics found reduced expression of HSD17B13 in carriers of the protective ‐TA allele. MTARC1 levels were unaffected by genotype. Both variants were associated with down‐regulation of fibrogenic pathways. HSD17B13 perturbs plasma phosphatidylcholines and triglycerides. In silico modeling suggested p.Ala165Thr disrupts the stability and metal binding of MTARC1. Conclusion: Both HSD17B13 and MTARC1 variants are associated with less severe pediatric NAFLD. These results provide further evidence for shared genetic mechanisms between pediatric and adult NAFLD.